Leadstar Biotech and Gewuzhihe signed a strategic cooperation agreement on the research and development of innovative tumor drugs

On May 20, 2021, Leadstar Biotechnology (Shanghai) Co.
, Ltd.
and Gewuzhihe Biotechnology (Beijing) Co.
, Ltd.
signed a strategic cooperation agreement to form a close strategic partnership
.

The two parties announced that they will conduct in-depth cooperation in the field of oncology drug companion diagnostics research and development, and jointly promote more innovative drug research and development processes, benefiting local and global patients in China
.

According to the agreement, Leadstar Biosciences will start from the real-world clinical + molecular data of Chinese cancer patients, and provide Gewuzhi with the Leadstar Knowledge Base System and Leadstar Knowledge Base API services to develop the indications and clinical aspects of the target compound.
Development strategy consulting, new drug and drug combination strategy development consulting services, and cooperation with Gewuzhihe to carry out prospective or retrospective clinical research to promote the development and commercialization of innovative tumor drugs
.

Leadstar Bio has been committed to using artificial intelligence data algorithms to correlate molecular mechanisms, disease populations, and clinical significance, and explore the three research mechanisms in clinical transformation and reverse transformation, to help patients obtain precise treatments and support the precise development of pharmaceutical companies Vision
.

Gewuzhihe focuses on the fields of scientific research and clinical medicine, and is committed to building a digital multi-omics platform to provide full-process innovative technology products and services for early warning and prevention of diseases, precise diagnosis, individualized treatment, and drug development
.

The signing of this strategic cooperation agreement is the first step in the complementary and coordinated development of Leading Biotech and Gewuzhi
.